Posted by Michael Wonder on 20 Mar 2025
Travere Therapeutics submits sNDA to FDA for approval of Filspari (sparsentan) for the treatment of focal segmental glomerulosclerosis
17 March 2025 - sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of Filspari in focal segmental glomerulosclerosis.
Travere Therapeutics today announced the Company has submitted a supplemental new drug application to the US FDA seeking priority review for traditional approval of Filspari (sparsentan) for the treatment of focal segmental glomerulosclerosis.
